KLRAKailera Therapeutics, Inc.
$11.61
$11.61
$9.9852 weeks$26.00
KLRA in its own filings
Nothing in KLRA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
5
Events found in the filings · across 62 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 10-Q
- Record starts
- Apr 20, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 11, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- May 26, 2026Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates.Earnings release · press release
- Apr 20, 2026On April 20, 2026, the Company completed its IPO of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at a public offering price of $16.00 per share.Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry